ReviewTransfusion medicine reviews2017
Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond.
Review in Transfusion medicine reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Shear-Responsive Red Blood Cell Carriers for Targeted Drug Delivery to Constricted Arteries.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Erythrocyte-inspired biomaterials for cancer immunotherapy: Integration within the cancer-immunity cycle.Materials today. Bio · 2026Review
- Biomimetic Targeted Drug Delivery for Liver Failure in Abdominal Sepsis: Focus on Autologous Erythrocyte Ghosts.International journal of molecular sciences · 2026Review
- Cell-drug conjugates: a novel drug delivery system for cancer therapy.Theranostics · 2026Review
- Single coadministration of erythrocyte-uricase conjugate and immunosuppressant induces durable immune tolerance for gout therapy.Science advances · 2025Article
- Article
- Advances in drug delivery systems utilizing blood cells and their membrane-derived microvesicles.Drug delivery · 2024Review
- Stem cell factor and erythropoietin-independent production of cultured reticulocytes.Haematologica · 2024Article
- Developing an erythrocyte‒MHC-I conjugate for cancer treatment.Cell discovery · 2024Article
- Emerging delivery strategy for oncolytic virotherapy.Molecular therapy. Oncology · 2024Review
- Exosomes in diagnostic and therapeutic applications of ovarian cancer.Journal of ovarian research · 2024Review
- Berberine mediated fluorescent gold nanoclusters in biomimetic erythrocyte ghosts as a nanocarrier for enhanced photodynamic treatment.RSC advances · 2024Article
- Drug-loaded erythrocytes: Modern approaches for advanced drug delivery for clinical use.Heliyon · 2024Review
- Red blood cells in biology and translational medicine: natural vehicle inspires new biomedical applications.Theranostics · 2024Review
- Translational Challenges and Prospective Solutions in the Implementation of Biomimetic Delivery Systems.Pharmaceutics · 2023Review
- Compatibility of Nucleobases Containing Pt(II) Complexes with Red Blood Cells for Possible Drug Delivery Applications.Molecules (Basel, Switzerland) · 2023Article
- Drug Delivery Systems in Regenerative Medicine: An Updated Review.Pharmaceutics · 2023Review
- Drug transport by red blood cells.Frontiers in physiology · 2023Review
- Cell-based carrier for targeted hitchhiking delivery.Drug delivery and translational research · 2022Review
- "Targeting Design" of Nanoparticles in Tumor Therapy.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Red blood cells (RBCs) are innate carriers that can also be engineered to improve the pharmacokinetics and pharmacodynamics of many drugs, particularly biotherapeutics. Successful loading of drugs, both internally and on the external surface of RBCs, has been demonstrated for many drugs including anti-inflammatory, antimicrobial, and antithrombotic agents. Methods for internal loading of drugs within RBCs are now entering clinical use. Although internal loading can result in membrane disruption that may compromise biocompatibility, surface loading using either affinity or chemical ligands offers a diverse set of approaches for the production of RBC drug carriers. A wide range of surface determinants is potentially available for this approach, although there remains a need to characterize the effects of coupling agents to these surface proteins. Somewhat surprisingly, recent data also suggest that red cell-mediated delivery may confer tolerogenic immune effects. Questions remaining before widespread application of these technologies include determining the optimal loading protocol, source of RBCs, and production logistics, as well as addressing regulatory hurdles. Red blood cell drug carriers, after many decades of progress, are now poised to enter the clinic and broaden the potential application of RBCs in blood transfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.